 Retreatment
"Retreatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
| Descriptor ID |
D019233
|
| MeSH Number(s) |
E02.887
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retreatment".
Below are MeSH descriptors whose meaning is more specific than "Retreatment".
This graph shows the total number of publications written about "Retreatment" by people in UAMS Profiles by year, and whether "Retreatment" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 3 | 3 | | 2020 | 0 | 2 | 2 | | 2019 | 0 | 2 | 2 | | 2017 | 0 | 5 | 5 | | 2016 | 0 | 11 | 11 | | 2015 | 0 | 2 | 2 | | 2014 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2011 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Retreatment" by people in Profiles over the past ten years.
-
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. Eur J Haematol. 2024 Aug; 113(2):190-200.
-
Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol. 2023 Jun; 110(6):626-632.
-
Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021 Nov 12; 21(1):1207.
-
Charlton-Ouw KM, Ikeno Y, Bokamper M, Zakhary E, Smeds MR. Aortic endograft sizing and endoleak, reintervention, and mortality following endovascular aneurysm repair. J Vasc Surg. 2021 11; 74(5):1519-1526.e2.
-
Demonchy J, Cordier C, Fr?alle E, Demarquette H, Herbaux C, Escure G, Willaume A, Van De Wyngaert Z, Noel MP, Facon T, Faure K, Caro J, Morgan G, Davies FE, Alfandari S, Bories C, Boyle EM. Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma. Clin Lymphoma Myeloma Leuk. 2021 06; 21(6):e545-e547.
-
Wiles S, Mireles-Cabodevila E, Neuhofs S, Mukhopadhyay S, Reynolds JP, Hatipoglu U. Endotracheal Tube Obstruction Among Patients Mechanically Ventilated for ARDS Due to COVID-19: A Case Series. J Intensive Care Med. 2021 May; 36(5):604-611.
-
Brown S, Pawlyn C, Tillotson AL, Sherratt D, Flanagan L, Low E, Morgan GJ, Williams C, Kaiser M, Davies FE, Jenner MW. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):154-161.e3.
-
Krajcer Z, Ramaiah VG, Henao EA, Nelson WK, Moursi MM, Rajasinghe HA, Anderson LH, Miller LE. Comparison of perioperative costs with fast-track vs standard endovascular aneurysm repair. Vasc Health Risk Manag. 2019; 15:385-393.
-
Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):570-578.e1.
-
Battle B, Sexton KW, Fitzgerald RT. Understanding the Value of Repeat Head?CT in Elderly Trauma Patients on Anticoagulant?or?Antiplatelet Therapy. J Am Coll Radiol. 2018 02; 15(2):319-321.
-
Trindade AJ, Inamdar S, Sejpal DV. Nitrous oxide CryoBalloon therapy of refractory gastric antral vascular ectasia. Endoscopy. 2017 09; 49(9):923-924.
-
Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017 Aug; 92(8):E146-E152.
-
Petit CJ, Glatz AC, Qureshi AM, Sachdeva R, Maskatia SA, Justino H, Goldberg DJ, Mozumdar N, Whiteside W, Rogers LS, Nicholson GT, McCracken C, Kelleman M, Goldstein BH. Outcomes After Decompression of the Right Ventricle in Infants With Pulmonary Atresia With Intact Ventricular Septum Are Associated With Degree of Tricuspid Regurgitation: Results From the Congenital Catheterization Research Collaborative. Circ Cardiovasc Interv. 2017 May; 10(5).
-
Luat AF, Asano E, Kumar A, Chugani HT, Sood S. Corpus Callosotomy for Intractable Epilepsy Revisited: The Children's Hospital of Michigan Series. J Child Neurol. 2017 06; 32(7):624-629.
-
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
-
Banerjee S, Jeon-Slaughter H, Tsai S, Mohammad A, Foteh M, Abu-Fadel M, Gigliotti OS, Cawich I, Rodriguez G, Kumbhani D, Addo T, Luna M, Das TS, Prasad A, Armstrong EJ, Shammas NW, Brilakis ES. Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions. JACC Cardiovasc Interv. 2016 11 14; 9(21):2243-2252.
-
McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Jan; 144(1):101-106.
-
Motaganahalli RL, Smeds MR, Harlander-Locke MP, Lawrence PF, Fujimura N, DeMartino RR, De Caridi G, Munoz A, Shalhub S, Shin SH, Amankwah KS, Gelabert HA, Rigberg DA, Siracuse JJ, Farber A, Debus ES, Behrendt C, Joh JH, Saqib NU, Charlton-Ouw KM, Wittgen CM. A multi-institutional experience in adventitial cystic disease. J Vasc Surg. 2017 Jan; 65(1):157-161.
-
Nabaweesi R, Ramakrishnaiah RH, Rettiganti MR, Luo C, Glasier CM, Maxson RT, Aitken ME, Kenney PJ, Robbins JM. The Clinical Impact of a Web-Based Image?Repository on Radiation Exposure in?Injured Children. J Am Coll Radiol. 2016 Nov; 13(11):1397-1403.
-
Sriskandarajah P, Pawlyn C, Mohammed K, Dearden CE, Davies FE, Morgan GJ, Boyd KD, Kaiser MF. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leuk Lymphoma. 2017 02; 58(2):494-497.
-
Timaran DE, Knowles M, Soto-Gonzalez M, Modrall JG, Tsai S, Kirkwood M, Rectenwald J, Timaran CH. Gender and perioperative outcomes after fenestrated endovascular repair using custom-made and off-the-shelf devices. J Vasc Surg. 2016 Aug; 64(2):267-272.
-
Ganesan C, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, Dudek AZ. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. Am J Clin Oncol. 2016 06; 39(3):280-7.
-
Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, D?ll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Br?ndlein S. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. Clin Cancer Res. 2016 Sep 01; 22(17):4341-9.
-
Gifford SM, Duncan AA, Greiten LE, Gloviczki P, Oderich GS, Kalra M, Fleming MD, Bower TC. The natural history and outcomes for thoracic and abdominal penetrating aortic ulcers. J Vasc Surg. 2016 05; 63(5):1182-8.
-
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma. 2016 10; 57(10):2359-69.
-
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
-
Hopper AB, Vilke GM, Castillo EM, Campillo A, Davie T, Wilson MP. Ketamine use for acute agitation in the emergency department. J Emerg Med. 2015 Jun; 48(6):712-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|